The Danish company “Novo Nordisk” announced that the US Food and Drug Administration has agreed to use Ozmbek to reduce the risk of exacerbation of kidney disease and kidney failure (kidney disease in the last stage, in which the patient needs dialysis or cultivation), and death due to cardiovascular disease in adults Those with type 2 diabetes and chronic kidney disease.
A diagonal drug license for kidney disease is a great addition in the field of health care due to the limited therapeutic options available to kidney patients.
The company published the announcement on its official website on January 28, and the New York Times wrote about it.
And Ozambek It is the brand name of the active substance, which is a category of medicines called “Betkid-1 Bulka-1”, which works by association with the “peptide-1” similar receptors to stimulate insulin secretion from the pancreas when the body needs it.
It also helps to reduce the amount of sugar secreted by the liver, and slows the exit of food from The stomach, these effects combined help reduce the measurement of cumulative sugar in the blood, and reduce appetite for food.
One of the main causes leading to chronic kidney disease leads to diabetes in the second type of diabetes leads to the blood vessels in the kidneys, which impedes its ability to liquidate blood from waste.
How to protect the drug or kidney patients?
Ozmbek drug works as an effective treatment, and contributes to reducing the possibility of a kidney condition or kidney failure in these patients, in addition to this may provide protection from death caused by cardiovascular problems.
Dr. Stephen Joe – the first deputy head of international medical affairs at Novo Nordisk, says the company manufacturer of Ozmbek – in an interview with the New York Times “over the past 20 years, the researchers have been working hard in this field, but the results were very limited, so the Reaching new results in this regard is very exciting, which will provide new hope for future patients. “
The Food and Drug Administration has relied in this decision on studies that showed that the use of diabetics and chronic kidney patients this drug leads to a decrease in the possibility of serious complications related to these diseases by 24% compared to those who received a fake treatment, and among these complications that have been significantly reduced their risk The need for dialysis or cultivation.
In addition, a decrease in the percentage of deaths from cardiovascular diseases has been observed among patients who used this drug.
The accurate mechanism for the work of Ozmbek is not clearly disclosed in treating kidney disease, but researchers are likely that the drug works to reduce infections throughout the body, including the kidneys.